EDAP TMS Reports Strong HIFU Growth Amid Declining Overall Revenue
Event summary
- EDAP TMS reported a 39% year-over-year increase in HIFU revenue for full-year 2025, driven by strong demand for Focal One® systems.
- Focal One® system placements grew by 69% year-over-year, with 14 cash sales and one operating lease in Q4 2025.
- U.S. procedures using the Focal One® system increased by 28% year-over-year in Q4 2025, marking the second consecutive quarter of double-digit growth.
- Overall revenue declined by 7% year-over-year in Q4 2025 due to lower revenue from non-core businesses (ESWL and Distribution).
- The company reiterated its 2026 revenue guidance, expecting HIFU revenue to grow between 34% and 45% year-over-year.
The big picture
EDAP TMS's strong performance in its HIFU business, particularly with the Focal One® system, highlights the growing acceptance of robotic energy-based therapies in treating early-stage prostate cancer. The company's strategic focus on expanding its HIFU business while phasing out non-core businesses reflects a broader industry trend towards specialization and innovation in medical technology.
What we're watching
- Market Adoption
- The pace at which Focal One® systems are adopted by academic cancer centers, community hospitals, and large integrated healthcare networks will be a key indicator of the company's growth trajectory.
- Financial Performance
- Whether EDAP TMS can sustain its strong HIFU revenue growth while managing declining overall revenue from non-core businesses will be crucial for its financial health.
- Regulatory and Clinical Data
- How the growing clinical data and increasing patient demand for non-invasive treatment options will impact the adoption of Focal One® systems in the global market.
Related topics